HTMTHM: Evaluating the Use of a Remote Telehome Monitoring Hypertension Program for Patients Receiving Virtual Care

Sponsor
Ottawa Heart Institute Research Corporation (Other)
Overall Status
Recruiting
CT.gov ID
NCT05300503
Collaborator
(none)
100
1
2
15.9
6.3

Study Details

Study Description

Brief Summary

High blood pressure or hypertension (HTN) is very common and can lead to serious health issues and even death. Medications and lifestyle changes can be used to treat HTN. During the Coronavirus Disease-19 (COVID-19) pandemic, a lot of the care provided by doctors has become virtual, meaning that patients can be assessed by a doctor over the phone or video call without needing to go to a clinic or hospital. Although this is convenient, a lot of people cannot get their blood pressure (BP) checked in a reliable way when they are at home. As a result, it is possible that their BPs are too high and that they are not getting the right medications or the right doses of medications to treat this. The Investigators are performing this study to see how patients are managing to check their BP's at home, during this time when a lot of the care is virtual. The Investigative team understands that many patients diagnosed with HTN don't have a home BP cuff, or might not know how to properly use it, or might not share the results with their doctors. In people who have high BP, we want to see if a special BP cuff and special monitoring program can help to get their BP's under better control, and to prevent negative effects related to HTN.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Telehome Monitoring
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants will be randomly assigned in a 1:1 fashion to either the control group or intervention group.Participants will be randomly assigned in a 1:1 fashion to either the control group or intervention group.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Evaluating the Use of a Remote Telehome Monitoring and Management Hypertension Program for Patients Receiving Virtual Care: A Pilot Randomized Controlled Trial
Actual Study Start Date :
Aug 4, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

Participants will be asked to continue their usual day to day activities and take their current medications as directed. They will be sent a link by email or through MyChart to the standard video & education session on managing hypertension. They will watch the video at home on their own time. Participants will use a home blood pressure monitor to track their blood pressure (those without a blood pressure cuff will be provided one) for the 3-month intervention period. Patients will be provided instructions of when they should seek medical attention (clinical symptoms or SBP <100 or SBP >160). They will be encouraged to track their blood pressure daily and any symptoms they may be feeling.

Experimental: Intervention

Participants will be asked to continue their usual day to day activities and take their current medications as directed. They will be sent a link by email or through MyChart to the educational session described above in the control group section. They will receive an Aetonix aTouchAway platform monitor, which is a disease specific home monitoring device to take home for 3 month intervention period. The device will prompt the participant to check their blood pressure on a daily basis and will send all readings to the UOHI Telehome monitoring program. The telehome monitoring nursing team will monitor the readings for each participant. For hypertensive patients who are not at target with their BP, the telehome monitoring nurse will titrate medications based on an advanced medical directive every 2 weeks. Patients will be provided instructions of when they should seek medical attention (clinical symptoms or SBP <100 or SBP >160).

Behavioral: Telehome Monitoring
Participants are enrolled into the Telehome Monitoring program

Outcome Measures

Primary Outcome Measures

  1. Current state of blood pressure control in virtual settings [3 months]

    To document the status of blood pressure control (both systolic and diastolic) in virtual hypertension care settings.

  2. Blood pressure response [3 months]

    Our primary outcome, which is the 24-hour ABPM, will be used to measure BP response in the control & intervention group at baseline & after 3-months of the intervention. We will repeat the 24-hour ABPM at 6-months follow up (3-months after completion of the intervention) to assess if there is maintenance of the intervention effects over time. Both systolic and diastolic measurements will be assessed.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Have a diagnosis of primary, essential HTN (SBP>140/90mmHg or >130/80mmHg for diabetes)

  • Have access to a phone (can be a landline)

  • Have access to cellular (4G) network at their primary residence (they do not need to physically own a cellular phone but the need to be able to confirm their residence has 4G network access in order to connect the Aetonix aTouchAway platform to the network)

  • Speak English or French

Exclusion Criteria:
  • Patients who have been referred or who are actively managed at a specialized HTN clinic or other Telehome monitoring program

  • Women who are pregnant, breastfeeding or planning to become pregnant

  • Patients who are institutionalized at a retirement home, nursing home or long-term care facility

  • Patients who plan on travelling out of the country for more than 2 weeks at any point during the intervention phase of the study (first 3 months)

  • Patients who are cognitively impaired or experiencing acute psychiatric illness that would alter their ability to participate

Contacts and Locations

Locations

Site City State Country Postal Code
1 The University of Ottawa Heart Institute Ottawa Ontario Canada K1Y4W7

Sponsors and Collaborators

  • Ottawa Heart Institute Research Corporation

Investigators

  • Principal Investigator: Hassan Mir, MD, Ottawa Heart Institute Research Corporation

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ottawa Heart Institute Research Corporation
ClinicalTrials.gov Identifier:
NCT05300503
Other Study ID Numbers:
  • 20210851-01H
First Posted:
Mar 29, 2022
Last Update Posted:
Aug 15, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 15, 2022